Exosomes are the most-hyped non-surgical hair therapy of the last few years. Our position is restrained: the early evidence is encouraging, the regulatory and quality-control questions are real, and most patients are better served by treatments with longer track records.
Exosomes are tiny extracellular vesicles released by cells — typically by stem cells in the lab — that carry proteins, lipids, and RNA molecules. They’re a primary mechanism cells use to communicate with one another. The hypothesis behind exosome therapy in hair restoration is that injecting concentrated exosomes into the scalp can stimulate dormant follicles to re-enter the active growth phase.
The early in-vitro and small clinical studies are promising. Several measure increased hair density and follicle thickness over 3–6 months in early-stage hair loss patients. The biology is plausible; the data is real.
Regulatory: Exosome products are not FDA-approved or Health Canada-approved for hair restoration. They’re typically marketed as “cosmetic” or as research products — which means quality control and dosing standardisation vary substantially between suppliers.
Source variability: Exosomes derived from umbilical-cord-derived stem cells, adipose-derived stem cells, and bone-marrow-derived stem cells all have different molecular profiles. The clinical evidence is split across these sources, and it’s not yet clear which produces the best hair-restoration outcome.
Cost-benefit relative to alternatives: For most early-stage patients, the proven medical therapies — finasteride, minoxidil, sometimes PRP — produce comparable or better outcomes at lower cost and with longer track records.
We don’t recommend exosomes as a first-line treatment. For most patients, the evidence-based approach is finasteride and/or minoxidil for early stages, surgery for established patterns, and PRP as a supportive adjunct in select cases. Exosomes are interesting research; they’re not yet a replacement for what works.
We’re actively monitoring the evidence. If a regulated, standardised exosome product with strong RCT data becomes available, we’ll add it to the toolkit. Until then, we’d rather be honest about what we don’t yet know than charge for an unproven treatment.
Send photos for an honest read. Dr. Jones will recommend what fits your case based on actual evidence, not on what’s trending in industry marketing.